Abstract 622P
Background
The modified mCCS intends to predict overall survival (OS) of mCRC patients (pts) at start of 1L therapy. Five clinical routine parameters assign pts into three prognostic risk groups from low to intermediate and high risk: tumor stage, tumor grading, lymph node ratio, primary tumor resection status and number of metastatic sites at start of 1L treatment (Marschner N, et al. Colorectal Dis. 2019). VALIDATE (NCT03043950) prospectively validates the mCCS in a large patient cohort with RAS WT mCRC.
Methods
VALIDATE is a multicenter, non-interventional study evaluating real-world effectiveness, safety and quality of life in pts with RAS WT mCRC receiving 1L PAN plus FOLFIRI/FOLFOX. Pts were allocated to three mCCS risk groups. This second interim analysis (IA2) was performed 24 months after last patient in. Data were analyzed descriptively for effectiveness, response rates and secondary resection rates.
Results
At data-base cut (Nov 17, 2022), 611 pts from 108 German and 5 Austrian sites were evaluable. Median age was 66.1 years, 68.9% of pts were male and 83.3% had an ECOG performance status 0/1. 59.4% of pts were diagnosed with a colon tumor. 84.3% of these pts had a left-sided tumor.
Table: 622P
Total N=611 | mCCS | |||
Low risk N=202 | Intermediate risk N=198 | High risk N=211 | ||
Overall response rate n (%) | 381 (62.4%) | 121 (59.9%) | 128 (64.6%) | 132 (62.6%) |
Secondary resections n (%) | 115 (18.8%) | 43 (21.3%) | 47 (23.7%) | 25 (11.8%) |
24-month OS rate [95%-CI] | 54.2% [50.0, 58.3] | 60.0% [52.4, 66.8] | 61.3% [53.8, 67.9] | 42.3% [35.3, 49.0] |
Most common grade 3/4 (MedDRA v20.0) treatment-emergent adverse drug reactions (TEADR) were dermatitis acneiform (5.8%), rash (2.9%) and diarrhea (3.2%). One investigator assessed fatal TEADR (arterial embolism) occurred.
Conclusions
The IA2 showed favorable effectiveness for PAN plus FOLFIRI/FOLFOX in the total population and in all mCCS risk groups in clinical routine in Germany and Austria. Interestingly, rates of secondary resections were >20% for low and intermediate risk pts. mCCS predicting OS will be validated in the final analysis. No new safety signals emerged.
Clinical trial identification
NCT03043950.
Editorial acknowledgement
Legal entity responsible for the study
iOMEDICO AG.
Funding
Amgen.
Disclosure
M. Reiser: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J. Uhlig: Financial Interests, Personal and Institutional, Advisory Board: Roche, Amgen, Servier, MSD, Bristol Myers Squibb, Sanofi, Merck, Celgene, Novartis, Janssen-Cilag, Boehringer Ingelheim, Bayer, BeiGene; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. L. Jacobasch, L. Mueller: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Schuch, L. Serrer, R. de Buhr: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. H.U. Siebenbach: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. T. Göhler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J.K. Schröder: Financial Interests, Personal and Institutional, Advisory Board: Celgene, Roche, Bristol Myers Squibb, Clovis Oncology, GSK, Boehringer Ingelheim, Amgen, Novartis, MSD, AOP, Searchlight, Pharma Partner, Medicline, Eisai, HE Research, Octapharma, AbbVie, NIO, I+E Pharma, ISPEN, BeiGene, Milteny; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. D. Semsek: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Koehler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE; Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Amge, Daiichi Sankyo MSD. P. Stübs: Non-Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. K.M. Potthoff: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. N.W. Marschner: Non-Financial Interests, Personal and Institutional, Invited Speaker: Amgen, BeiGene, Roche, GSK, Euspharm, stemline, Seagen, Servier; Non-Financial Interests, Personal and Institutional, Advisory Board: Amgen, AstraZeneca, BeiGene, , Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier Stemline; Financial Interests, Personal and Institutional, Member of Board of Directors: iOMEDICO; Financial Interests, Personal and Institutional, Full or part-time Employment: iOMEDICO; Financial Interests, Institutional, Ownership Interest: iOMEDICO; Non-Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Non-Financial Interests, Institutional, Funding: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Financial Interests, Personal, Project Lead: iOMEDICO/VALIDATE.
Resources from the same session
590P - Assessment of circulating tumor (ct)DNA in patients (pts) with locally advanced rectal cancer (LARC) pts treated with neoadjuvant therapy (NAT)
Presenter: Chiara Molinari
Session: Poster session 10
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10